10.03.19
A recent clinical paper reporting on the use of Sabinsa’s Curcumin C3 Complex and BioPerine, and taurine on hepatocellular carcinoma (HCC) patients was published in the Journal of Gastrointestinal Oncology.
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, representing the fifth and the eighth largest cause of cancer in men and women, respectively. Further, it is considered the third most lethal cancer worldwide with about 700,000 deaths reported annually. It is often treated with some surgical choices but plagued with high recurrence. Organ transplant and chemotherapy are possible solutions, again, limited in scope. The search for additional treatments is ongoing.
The present study covered 20 patients in a single center, open-arm, Phase II study with HCC patients recruited at the medical oncology clinic at National Cancer Institute, Cairo University. The study involved three treatment cycles, with measurement of the levels of AST, ALT, Albumin, total bilirubin, AFU (Alpha-L-fucosidase, an often-recommended serum biomarker in HCC) and IL-10 after each treatment cycle. All the parameters showed improvement compared to baseline levels, progressively with each succeeding cycle. One other primary endpoint in this study was the levels of oncogenic micro RNA-21, which showed statistically significant decrease in these patients on this treatment. The median overall survival (OS) rate was 17 months with patients with lower IL-10 and microRNA-21 having higher OS.
“Sabinsa has been marketing Curcumin C3 Complex, and the natural bioavailability enhancer, BioPerine each with a rich history of use in many preclinical and clinical studies covering numerous health conditions, for more than quarter of a century,” said Sabinsa founder Dr. Muhammed Majeed. “This publication continues to reinforce the benefits of both of them.”
This study can be accessed online here.
Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver, representing the fifth and the eighth largest cause of cancer in men and women, respectively. Further, it is considered the third most lethal cancer worldwide with about 700,000 deaths reported annually. It is often treated with some surgical choices but plagued with high recurrence. Organ transplant and chemotherapy are possible solutions, again, limited in scope. The search for additional treatments is ongoing.
The present study covered 20 patients in a single center, open-arm, Phase II study with HCC patients recruited at the medical oncology clinic at National Cancer Institute, Cairo University. The study involved three treatment cycles, with measurement of the levels of AST, ALT, Albumin, total bilirubin, AFU (Alpha-L-fucosidase, an often-recommended serum biomarker in HCC) and IL-10 after each treatment cycle. All the parameters showed improvement compared to baseline levels, progressively with each succeeding cycle. One other primary endpoint in this study was the levels of oncogenic micro RNA-21, which showed statistically significant decrease in these patients on this treatment. The median overall survival (OS) rate was 17 months with patients with lower IL-10 and microRNA-21 having higher OS.
“Sabinsa has been marketing Curcumin C3 Complex, and the natural bioavailability enhancer, BioPerine each with a rich history of use in many preclinical and clinical studies covering numerous health conditions, for more than quarter of a century,” said Sabinsa founder Dr. Muhammed Majeed. “This publication continues to reinforce the benefits of both of them.”
This study can be accessed online here.
